MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France; Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium.
MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France.
Drug Discov Today. 2018 Feb;23(2):416-423. doi: 10.1016/j.drudis.2017.10.010. Epub 2017 Oct 23.
Gemcitabine is a nucleoside analog currently used for the treatment of various solid tumors as a single agent or in combination with other chemotherapeutic drugs. Its use against highly aggressive brain tumors (glioblastoma) has been evaluated in preclinical and clinical trials leading to controversial results. Gemcitabine can inhibit DNA chain elongation, is a potent radiosensitizer and it can enhance antitumor immune activity, but it also presents some drawbacks (e.g., short half-life, side effects, chemoresistance). The aim of this review is to discuss the challenges related to the use of gemcitabine for glioblastoma and to report recent studies that suggest overcoming these obstacles opening new perspectives for its use in the field (e.g., gemcitabine derivatives and/or nanomedicines).
吉西他滨是一种核苷类似物，目前被用作单一药物或与其他化疗药物联合治疗各种实体肿瘤。针对高度侵袭性脑肿瘤（胶质母细胞瘤）的临床前和临床试验已经评估了其用途，但结果存在争议。吉西他滨可以抑制 DNA 链延伸，是一种有效的放射增敏剂，并且可以增强抗肿瘤免疫活性，但它也存在一些缺点（例如半衰期短、副作用、化疗耐药性）。本综述旨在讨论与胶质母细胞瘤中使用吉西他滨相关的挑战，并报告最近的研究，这些研究表明可以克服这些障碍，为其在该领域的应用开辟新的前景（例如，吉西他滨衍生物和/或纳米药物）。
